

## **SOUTHWEST NODE**

The Southwest Node includes the University of New Mexico Center on Alcoholism, Substance Abuse and Addictions (CASAA) and seven community treatment programs providing inpatient and outpatient, urban and rural psychotherapy and pharmacotherapy. New Mexico is the first “minority majority” state, and its clinical populations include large proportions of Native American and Hispanic clients.

## **TEXAS NODE**

The Texas Node comprises the University of Texas Southwestern Medical Center in Dallas (UT Southwestern) and seven CTPs in Dallas, Ft. Worth, Austin, and El Paso. UT Southwestern brings together a faculty with extensive experience in the preclinical and clinical study of substance use disorders, the design, implementation, and analysis of multi-site, efficacy-effectiveness clinical trials in both adolescents and adults, the pharmacological treatment of comorbid disorders, and cultural issues in addiction. UT Southwestern faculty collaborate with CTPs representing over 11,000 annual inpatient and outpatient admissions for a primary substance use disorder, with large populations of Hispanic/Latino, African-American, adolescent, and female patients. The CTPs and associated sites also offer specialized treatment and outreach programs for HIV positive patients.

## **WASHINGTON NODE**

The Washington Node includes the Alcohol and Drug Abuse Institute at the University of Washington, and eight community treatment programs distributed geographically over Washington State. These programs provide a mix of settings including: urban and rural, private and public sector, in-patient/residential and outpatient, and drug free and methadone maintenance programs. The CTPs provide a wide range of treatment services to nearly 12,000 clients per year. All available services are also targeted to specific groups having special needs such as women, the elderly, dual disorder clients, homeless populations, and adolescent clients.

## *For more information*

National Institute on Drug Abuse  
Center for the Clinical Trials Network  
6001 Executive Boulevard, Room 3105, MSC 9557  
Bethesda, Maryland 20892-9557

Telephone: (301) 443-6697 • Fax: (301) 443-2317  
Betty Tai, Ph.D., Director, Clinical Trials Network  
E-mail: btai@nih.gov

Further information on the Clinical Trials Network can be accessed through the NIDA website at [www.drugabuse.gov](http://www.drugabuse.gov).

## *CTN Nodes*

### **APPALACHIAN TRI-STATE**

Affiliation: University of Pittsburgh, Pittsburgh, PA  
Principal Investigator: Dennis C. Daley, Ph.D.  
E-mail: daleydc@upmc.edu

### **CALIFORNIA-ARIZONA**

Affiliation: University of California at San Francisco, San Francisco, CA  
Principal Investigator: James L. Sorensen, Ph.D.  
E-mail: james@itsa.ucsf.edu

### **DELAWARE VALLEY**

Affiliation: Trustees of the University of Pennsylvania, Philadelphia, PA  
Principal Investigator: George E. Woody, M.D.  
E-mail: woody@tresearch.org

### **FLORIDA**

Affiliation: University of Miami, Miami, FL  
Principal Investigator: José Szapocznik, Ph.D.  
E-mail: jszapocz@med.miami.edu

### **LONG ISLAND REGIONAL**

Affiliation: New York State Psychiatric Institute, New York, NY  
Principal Investigator: Edward V. Nunes, M.D.  
E-mail: nunesed@pi.cpmc.columbia.edu

### **MID-ATLANTIC**

Affiliation: The Johns Hopkins University, Baltimore, MD  
Principal Investigator: Maxine Stitzer, Ph.D.  
E-mail: mstitzer@mail.jhmi.edu

### **NEW ENGLAND**

Affiliation: Yale University, New Haven, CT  
Principal Investigator: Kathleen Carroll, Ph.D.  
E-Mail: kathleen.carroll@yale.edu

### **NEW YORK**

Affiliation: New York University, New York, NY  
Principal Investigator: John Rotrosen, M.D.  
E-mail: john.rotrosen@med.nyu.edu

### **NORTH CAROLINA**

Affiliation: Duke University, Durham, NC  
Principal Investigator: Robert L. Hubbard, Ph.D., M.B.A.  
E-mail: hubbard@ndri-nc.org

## *CTN Nodes*

### **NORTHERN NEW ENGLAND**

Affiliation: McLean Hospital, Belmont, MA  
Principal Investigator: Roger D. Weiss, M.D.  
E-mail: rweiss@mclean.harvard.edu

### **OHIO VALLEY**

Affiliation: University of Cincinnati, Cincinnati, OH  
Principal Investigator: Eugene Somoza, M.D., Ph.D.  
E-mail: somozae@email.uc.edu

### **OREGON/HAWAII**

Affiliation: Oregon Health Sciences University, Portland, OR  
Principal Investigator: Dennis McCarty, Ph.D.  
E-mail: mccartyd@ohsu.edu

### **PACIFIC REGION**

Affiliation: The Regents of the University of California, Los Angeles, Los Angeles, CA  
Principal Investigator: Walter Ling, M.D.  
E-mail: lwalter@ix.netcom.com

### **SOUTHERN CONSORTIUM**

Affiliation: Medical University of South Carolina, Charleston, SC  
Principal Investigator: Kathleen T. Brady, M.D., Ph.D.  
E-mail: bradyk@musc.edu

### **SOUTHWEST**

Affiliation: University of New Mexico, Albuquerque, NM  
Principal Investigator: William R. Miller, Ph.D.  
E-mail: wrmiller@unm.edu

### **TEXAS**

Affiliation: The University of Texas Southwestern Medical Center, Dallas, TX  
Principal Investigator: Bryon Adinoff, M.D.  
Email: bryon.adinoff@utsouthwestern.edu


### **WASHINGTON**

Affiliation: University of Washington, Seattle, WA  
Principal Investigator: Dennis M. Donovan, Ph.D.  
E-mail: ddonovan@u.washington.edu

**NIDA** NATIONAL INSTITUTE  
ON DRUG ABUSE

# *National Drug Abuse Treatment Clinical Trials Network*

*Forging partnerships to  
improve the quality of  
drug abuse treatment  
throughout the nation...*



National Institutes of Health  
U.S. Department of Health and Human Services

10/16/05

Revised October 2005

## What is the Clinical Trials Network?

To date, the efficacy of new treatments for drug addiction has been demonstrated primarily in specialized research settings, with somewhat restricted patient populations. To address this problem, the National Institute on Drug Abuse (NIDA) has established the National Drug Abuse Treatment Clinical Trials Network (CTN).

The mission of the CTN is twofold:

- \* Conduct studies of behavioral, pharmacological, and integrated behavioral and pharmacological treatment interventions of therapeutic effect in rigorous, multisite clinical trials to determine effectiveness across a broad range of community-based treatment settings and diversified patient populations; and
- \* Transfer the research results to physicians, providers, and their patients to improve the quality of drug abuse treatment throughout the country using science as the vehicle.

## Nodes

### APPALACHIAN TRI-STATE NODE

The Appalachian Tri-State Node (ATS) is a partnership between Western Psychiatric Institute & Clinic of the University of Pittsburgh Medical Center, West Virginia University School of Medicine, and five community treatment programs (CTPs) in Eastern Ohio, West Virginia, and Western Pennsylvania. This node serves over 15,000 patients annually in urban and rural settings in all types of addiction and dual disorder treatment programs. Special interests and capabilities of the ATS include treating patients in rural settings, those with co-occurring psychiatric disorders, adolescents, women with children, criminal justice involved clients, and opiate addicts in need of maintenance treatment. ATS also has a strong interest in training professionals, developing treatment manuals, and developing recovery materials for clients and their families.

### CALIFORNIA-ARIZONA NODE

The California-Arizona Research Node represents a partnership between researchers at the University of California, San Francisco and the University of Arizona, in collaboration with six CTPs operating in both urban and rural locations (San Francisco, Oakland, Sacramento, and Tucson areas). Participating CTPs, several of which have multiple sites, include hospital-based and community-based programs, and include residential, outpatient, and methadone treatment approaches. Collectively, these six CTPs serve a racially and ethnically diverse population of more than 16,000 patients per year.

### DELAWARE VALLEY NODE

The Delaware Valley Node is part of the Center for Studies of Addiction at the University of Pennsylvania and the Treatment Research Institute in Philadelphia; and is also affiliated with Thomas Jefferson University School of Medicine and the University of Medicine and Dentistry of New Jersey. There are 15 CTPs in its provider network; serving residents of New Jersey, Pennsylvania and Delaware; in addition, the DV Node includes one managed behavioral health care organization with over 500,000 Philadelphia area members. The DV Node member organizations provide services to patients with every type of substance use disorder including special populations such as: 1) persons living with HIV, 2) adolescents, 3) veterans, 4) women with children, and 5) patients living in rural areas.

### FLORIDA NODE

The Florida Node includes the Center for Family Studies in the Miller School of Medicine at the University of Miami and community treatment programs in Florida and Puerto Rico. These CTPs serve urban and semi-rural areas, and treat an ethnically and racially diverse population. The five founding CTPs are leaders in innovative service programs and the development of drug abuse treatment in the State of Florida. The node has considerable expertise in: 1) adolescent family treatment, 2) treatment for HIV/AIDS populations, 3) aggressive engagement of drug abusers into treatment, and 4) microanalysis of family therapy clinical process. The node has a special interest and expertise with Spanish speaking populations both in the US and abroad.

### LONG ISLAND REGIONAL NODE

The Long Island Node includes five community-based organizations with a total of over 50 treatment programs serving a culturally and ethnically diverse patient population. These programs encompass a wide variety of treatment modalities including inpatient and outpatient programs, detoxification programs, methadone maintenance, therapeutic communities, programs for adolescents, and programs for women with children. Areas of special interest and expertise within the node include: psychiatric and medical co-morbidity, HIV, adolescent treatment, women and trauma, and combined behavioral and pharmacotherapy.

### MID-ATLANTIC NODE

The Mid-Atlantic Node includes Johns Hopkins University School of Medicine, Virginia Commonwealth University, Friends Research Institute, and seven CTPs. The CTP network provides about 5,000 treatment slots serving a diverse group of people suffering from substance use disorder, which is often complicated by other psychiatric and medical illnesses.

### NEW ENGLAND NODE

The New England Node comprises five core CTPs and seven additional CTPs. These CTPs were selected on the basis of the size, breadth, and diversity of the populations they serve; volume and administrative efficiency, and commitment to evidence based treatments. The total number of unduplicated annual admission to substance use treatment is over 27,000. A wide array of treatment modalities is offered including: programs for HIV/HCV, treatment of adolescents, substance use and primary care, and psychiatric co-morbidity.

### NEW YORK NODE

The NY Node is a consortium of academic centers, clinical programs and local and regional agencies with a long track record of fruitful collaboration in research, training, service delivery, policy-making, funding, and advocacy for addictive disorders. Key academic institutions include New York University, The Rockefeller University, the Nathan Kline Institute, and the NY Academy of Medicine. Our 8 CTPs provide a wide range of programs and treatment models, and services for more than 13,000 patients with extensive diagnostic, ethnic, and gender diversity. NY Node CTPs have been at the forefront of translational research and have made a number of pioneering achievements including the establishment of the first outpatient narcotic detoxification clinic, the first non-hospital-based methadone program, the first methadone-to-abstinence residential community, and the first social work field training in addiction.

### NORTH CAROLINA NODE

The North Carolina Node is a partnership between Duke University, National Development and Research Institutes, the State of North Carolina and 12 community treatment programs distributed across the State. These programs, which include the major providers of treatment in North Carolina, serve more than 20,000 financially, culturally and ethnically diverse clients located in rural and urban settings. The programs include a therapeutic community, area mental health centers, private outpatient agencies, and regional residential addiction treatment centers. Treatments provided encompass a wide range of therapies, both behavioral and pharmacologic, for families, adolescents, and adults.

### NORTHERN NEW ENGLAND NODE

The Northern New England Node is a partnership between clinical addiction researchers at Harvard Medical School, other universities, and CTPs located in five New England states – Maine, Massachusetts, Rhode Island, New Hampshire, and Vermont. Together, the CTPs had over 48,000 admissions in 2001 for substance use disorders. The CTPs provide services to an ethnically diverse patient population with a variety of substance use disorders in rural, suburban, and urban

locales. Special populations include individuals with comorbid psychiatric and medical illnesses, HIV-infected individuals, adolescents, pregnant women, and individuals involved with the criminal justice system.

### OHIO VALLEY NODE

The Ohio Valley Node includes sixteen community treatment programs in Illinois, Indiana, Iowa, Kentucky, Minnesota, Missouri, Ohio, West Virginia, and Wisconsin, as well as researchers from the University of Cincinnati. The CTPs bring a large variety of substance abuse services and treat more than 54,000 patients per year. These patients live in both rural and urban areas and many are of Appalachian background.

### OREGON/HAWAII NODE

The Oregon/Hawaii Node is a bi-directional clinical trial partnership of two research and training organizations – Oregon Health & Science University with support from the Kaiser Permanente Center for Health Research in Honolulu, Hawaii – and eight multi-modality drug treatment programs located in urban and rural communities in Oregon, Hawaii, and Washington. These programs serve a growing number of Latino, Native American, Hawaiian, Russian, Asian, and female clients. Services are provided across the treatment continuum.

### PACIFIC REGION NODE

The Pacific Region Node is a partnership between the Regents of the University of California, Los Angeles and several community treatment programs in the State. The node incorporates researchers and clinicians from throughout California. Many of the CTP networks have been involved in the transfer of research into practice for over a decade. The diverse communities served by the CTPs have geographic areas with epidemic methamphetamine use, increasing rates of heroin use among youthful populations, endemic inner city crack cocaine use, and dramatically increasing reports of the use of ecstasy and GHB.

### SOUTHERN CONSORTIUM NODE

The Southern Consortium Node (formerly the South Carolina Node) comprises five research CTPs in South Carolina and Georgia as well as approximately 25 treatment centers in South Carolina, Georgia and Mississippi, who are members of the Southern Consortium. The consortium was formed to help facilitate promulgation of CTN findings and provide a larger pool of potential CTN research sites. The CTPs of the Southern Consortium provide services to adults and adolescents in both rural and urban areas and represent a wide range of treatment settings and modalities including 12-step, family therapy, medication management, inpatient detoxification, drug court, narcotic replacement therapy, and cognitive behavioral therapy.